1. Home
  2. JRVR vs AKBA Comparison

JRVR vs AKBA Comparison

Compare JRVR & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo James River Group Holdings Ltd.

JRVR

James River Group Holdings Ltd.

HOLD

Current Price

$3.52

Market Cap

209.9M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

BUY

Current Price

$0.88

Market Cap

248.3M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
JRVR
AKBA
Founded
2002
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
209.9M
248.3M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
JRVR
AKBA
Price
$3.52
$0.88
Analyst Decision
Hold
Buy
Analyst Count
3
6
Target Price
★ $4.72
$3.92
AVG Volume (30 Days)
296.9K
★ 5.6M
Earning Date
11-02-2026
11-09-2026
Dividend Yield
★ 1.17%
N/A
EPS Growth
★ 125.82
93.94
EPS
N/A
★ N/A
Revenue
★ $687,614,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$3.36
$0.81
52 Week High
$7.20
$3.19

Technical Indicators

Market Signals
Indicator
JRVR
AKBA
Relative Strength Index (RSI) 32.80 43.47
Support Level N/A $0.85
Resistance Level $4.26 $0.98
Average True Range (ATR) 0.12 0.05
MACD -0.01 0.00
Stochastic Oscillator 22.13 23.69

Price Performance

Historical Comparison
JRVR
AKBA

About JRVR James River Group Holdings Ltd.

James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: